| Host: |
HEK293 |
| Note: |
STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-COV2 Spike protein RBD B.1.1.529 (Omicron)-His-Tag protein was developed from hek293 and has a target region of His-Tag. For use in research applications. |
| Conjugation: |
Unconjugated |
| Formulation: |
Lyophilised from 0.2 µm filtered PBS solution pH7.4. |
| Dilution Range: |
Spin the vial and reconstite in distilled water to a concentration not less than 0.1 mg/mL. This can then be diluted into other buffers. |
| Storage Instruction: |
The lyophilized protein is stable for at least 1 year from date of receipt at-20°C. NA |
| Endotoxin: |
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). NA |
| Immunoreactivity: |
The activity was tested by binding Human ACE2 in functional ELISA assay (see figure below). NA |
| Immunogen Region: |
ECD |
| Immunogen: |
DNA sequence encoding extracellular fragment[319-541] of COV2 Spike RBD domain [accession# QIC53204.1] variant (B.1.1.529/Omicron) ( G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H) including a |
| Background | Recombinant COV2 RBD B.1.1.529 encodes the NCOV spike glycoprotein RBD domain sequence. This molecule has a calculated mass of approximately 76kDa. Recombinant COV2 RBD migrates due to glycosylation as an approximately 120 kDa protein under reducing conditions in SDS-PAGE. |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
